Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
13.44
+0.04 (+0.30%)
Official Closing Price
Updated: 4:00 PM EDT, Jul 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Catalyst's New CEO Has Big Ideas For The Small Biotech
May 10, 2024
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year.
Via
Investor's Business Daily
Japan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
May 09, 2024
Takeda Pharmaceutical (NYSE: TAK) reveals fiscal year 2023 results & restructuring plan. Revenue up 5.9%, net profit down 54.6%. Expecting operating profit of 225 billion yen in 2024.
Via
Benzinga
TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q4 2023
May 09, 2024
Takeda Pharmaceutical just reported results for the fourth quarter of 2023.
Via
InvestorPlace
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
May 09, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
April 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
April 26, 2024
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Neurocrine Biosciences Says Treatment Can Alleviate Several Symptoms Associated With Depressive Disorder
April 23, 2024
Neurocrine Biosciences reports Phase 2 data for NBI-1065845 in major depressive disorder. Results show significant improvement in MADRS scores. William Blair sees the potential for $1 billion+ in...
Via
Benzinga
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win
April 23, 2024
The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza.
Via
Investor's Business Daily
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
April 18, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
April 08, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
March 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
March 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
March 19, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders
March 19, 2024
From
Centogene NV
Via
GlobeNewswire
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
March 13, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
The Hot List: 3 AI Stocks Worth Buying on Weakness
March 01, 2024
Firms using AI directly can be great picks for long-term investors, such as these three AI stocks to buy on weakness.
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
February 26, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
FDA Approves Takeda's Eohilia As First Oral Treatment For Inflammed Esophagus
February 12, 2024
Eohilia: FDA-approved oral therapy for EoE. Takeda's innovative 2mg/10mL stick packs available by February. Histologic remission achieved in studies.
Via
Benzinga
Exposures
Product Safety
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
February 12, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Good News For Sleep Disorder Patients - Takeda's Therapy Shows Promise In Mid-Stage Study
February 09, 2024
Takeda's Phase 2b trial results for TAK-861, an oral orexin receptor 2 agonist, in narcolepsy type 1 patients. Global Phase 3 trials planned for fiscal year 2024.
Via
Benzinga
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
February 08, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Why Is Japanese Drugmaker Takeda Stock Trading Lower Today?
February 01, 2024
Takeda Pharmaceutical's Q3 2023 results: ¥235.9 billion core net profit, management changes, and a global collaboration deal for rusfertide. Fiscal year 2023 guidance reiterated.
Via
Benzinga
Takeda Announces Chief Financial Officer Succession
February 01, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Third-Quarter FY2023 Results; On-Track Towards Full-Year Management Guidance With Strong Momentum in Growth & Launch Products
February 01, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 29, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Earnings Scheduled For February 1, 2024
February 01, 2024
Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on...
Via
Benzinga
Takeda’s HYQVIA® Approved by European Commission as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
January 29, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
3 Stocks to Buy to Benefit From the Booming Sleep Industry
January 23, 2024
It’s not easy to find sleep stocks to buy despite the fact the industry is booming these days from society's lack of rest and relaxation.
Via
InvestorPlace
Takeda Named Global Top Employer for Seventh Consecutive Year
January 18, 2024
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Time to buy these 3 healthcare companies that raised revenue guidance?
January 16, 2024
The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance.
Via
MarketBeat
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.